CHF Solutions, Inc. Expands European Distribution with New Agreement in Italy
“According to the World Health Organization there are more than twice as many acute decompensated heart failure patients in Western Europe than in the United States as result of a larger and older population base, along with higher smoking patterns,” commented John Erb, chairman and chief executive officer of CHF Solutions. “We are pleased to continue expanding our market reach in Western Europe, and specifically in Italy with our new distributor partner, TRX Italy, a premier cardiovascular sales and distribution company to provide physicians in Italy with a clinically proven therapy for the treatment of fluid overload when diuretics are no longer effective.”
Terms of the agreement were not disclosed.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company’s mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
About TRX Italy S.r.L.
TRX Italy S.r.L. is a medical devices distributor focused on commercializing innovative cardiovascular solutions for heart failure. With twenty years of clinical, technical and commercial experience, the company’s sales network is particularly dedicated on promoting technologies that can preserve and improve the clinical and economic value of cardiac resynchronization therapies for advanced heart failure. The Acquadex FlexFlow ultrafiltration treatment represents for the Company another innovative solution to promote for improving the quality of life of heart failure patients. TRX Italy srl is headquartered in Bologna, Emilia Romagna and its sales network covers the entire national territory.
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
JQA Partners, Inc.